Imidazole as a Promising Medicinal Scaffold: Current Status and Future Direction
Sahar S Alghamdi,Rasha S Suliman,Khlood Almutairi,Khawla Kahtani,Dimah Aljatli
DOI: https://doi.org/10.2147/DDDT.S307113
2021-07-29
Abstract:Sahar S Alghamdi, 1, 2 Rasha S Suliman, 1, 2 Khlood Almutairi, 1 Khawla Kahtani, 1 Dimah Aljatli 1 1 College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Kingdom of Saudi Arabia; 2 Medical Research Core Facility and Platforms, King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs, Riyadh, Kingdom of Saudi Arabia Correspondence: Rasha S Suliman Tel +966 114299999 Ext 99570 Email Various imidazole-containing compounds have been tested for their medical usefulness in clinical trials for several disease conditions. The rapid expansion of imidazole-based medicinal chemistry suggests the promising and potential therapeutic values of imidazole-derived compounds for treating incurable diseases. Imidazole core scaffold contains three carbon atoms, and two nitrogen with electronic-rich characteristics that are responsible for readily binding with a variety of enzymes, proteins, and receptors compared to the other heterocyclic rings. Herein, we provide a thorough overview of the current research status of imidazole-based compounds with a wide variety of biological activities including anti-cancer, anti-microbial, anti-inflammatory and their potential mechanisms including topoisomerase IIR catalytic inhibition, focal adhesion kinase (FAK) inhibition, c-MYC G-quadruplex DNA stabilization, and aurora kinase inhibition. Additionally, a great interest was reported in the discovery of novel imidazole compounds with anti-microbial properties that break DNA double-strand helix and inhibit protein kinase. Moreover, anti-inflammatory mechanisms of imidazole derivatives include inhibition of COX-2 enzyme, inhibit neutrophils degranulation, and generation of reactive oxygen species. This systemic review helps to design and discover more potent and efficacious imidazole compounds based on the reported derivatives, their ADME profiles, and bioavailability scores that together aid to advance this class of compounds. Keywords: imidazole, apoptosis, kinase inhibitors, tubulin polymerization, topoisomerase II In the last century, nitrogen-based heterocycles, particularly the imidazole ring which was discovered in the 1840s, attracted many researchers as this core scaffold demonstrated promising anti-cancer, anti-microbial, and anti-inflammatory activities. 1 The structural features of the imidazole ring enhance their ability to form multiple drug–ligand interactions via hydrogen bonds, van der Waals, and hydrophobic forces. 2 Moreover, the imidazole core scaffold is a part of several naturally derived compounds, such as histamine, histidine, biotin, alkaloids, and nucleic acid, and a part of multiple classes of FDA-approved drugs. Because of their important properties as therapeutics, fused imidazole derivatives have held a prominent role in the medical field. Methotrexate, Metronidazole, and Omeprazole are the current imidazole derivatives available on market as anti-cancer, anti-microbial, and anti-inflammatory agents, respectively. Nevertheless, these drugs have shown painful and unacceptable side effects that caused treatment failure. 3 To discover potent compounds with better safety profiles, Imidazole-based compounds are under intensive scientific exploration as these derivatives have achieved amazing progression in medicinal chemistry research. The literature summarized in this review aids in the design and development of novel and highly potent compounds with less harmful side effects for the treatment of lethal human diseases. Cancer is the second major cause of death after cardiac disease nationally and internationally. The annual number of new cases is estimated to be 439.2 per 100,000 people. 4 At the current global rate, the estimated number of cancer is rapidly increasing and predicted to reach approximately 27.5 million new cancer cases per year by 2040. 5 Until today, the detailed mechanism of cancer is not fully understood and with a simple definition, it is considered to be a genetic disease that starts with abnormal and continuous cell growth, with the chance of metastasis. 6 The current chemotherapeutic agents available such as Methotrexate, Etoposide, and Paclitaxel demonstrated potent activity and to some extent, good survival rates, however, several challenges need to be overcome, such as drug resistance, toxicity, and intolerable side effects. 7 Thus, a new rationale for anticancer agents should be investigated to discover new targeted therapy with lower systemic side effects. 8</ -Abstract Truncated-